Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.
Principal Financial Group Inc. lessened its stake in Mesa Laboratories, Inc. (NASDAQ: MLAB) by 66.2% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,065 shares of the medical instruments supplier's stock after selling 19,713 shares during the quarter. Principal Financial Group
Diamond Hill Capital Management Inc. grew its holdings in shares of Mesa Laboratories, Inc. (NASDAQ: MLAB) by 218.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,381 shares of the medical instruments supplier's stock after purchasing an additional 84,582
Mesa Laboratories (NASDAQ: MLAB - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Tuesday, February 3rd. Analysts expect the company to announce earnings of $2.41 per share and revenue of $63.2330 million for the quarter. Individuals may visit the the company's upcoming Q3 2026 earning results page for
Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
LAKEWOOD, Colo., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026.
LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026. Management will participate in a Formal Presentation at 4:30 p.m. Pacific Time.
Mesa Laboratories (NASDAQ: MLAB - Get Free Report) and Accuray (NASDAQ: ARAY - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Institutional and Insider Ownership 90.6% of Mesa Laboratories
LAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that Gary Owens, President and CEO, and John Sakys, CFO will be attending the following upcoming conferences:
LAKEWOOD, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2026 following market close on Thursday, November 6, 2025.
Mesa Labs (MLAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
LAKEWOOD, Colo., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, “Mesa” or the “Company”) today announced that it has executed on its previously-announced financial strategy, repaying $97.5 million aggregate principal of the Company's 1.375% Convertible Senior Notes due August 2025 (the “2025 Notes”). On August 12, 2025, the Company drew $97.0 million under its existing Amended and Restated Credit Agreement (the “Credit Agreement”), bringing the total outstanding balance to $108 million. The proceeds from the draw were used to settle the 2025 Notes that matured on August 15, 2025.
Mesa Labs (MLAB) came out with quarterly earnings of $2.32 per share, missing the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.83 per share a year ago.
LAKEWOOD, Colo., July 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025.
LAKEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern time on Tuesday, August 5, 2025.
Mesa Labs (MLAB) came out with quarterly earnings of $2.23 per share, missing the Zacks Consensus Estimate of $2.75 per share. This compares to earnings of $2.77 per share a year ago.
LAKEWOOD, Colo., May 28, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q25”) and full fiscal year (“FY25”) ended March 31, 2025 (amounts in thousands).
LAKEWOOD, Colo., April 07, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.
Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.